The expression of secretory group IIA phospholipase A2 (sPLA2-IIA) has been shown to be elevated in various inflammatory diseases, and lipopolysaccharide (LPS) up-regulates the expression of sPLA2-IIA in human umbilical vein endothelial cells (HUVECs). Pelargonidin (PEL) is a well-known red pigment found in plants, and has been reported as having important biological activities that are potentially beneficial for human health. Here, PEL was examined for its effects on the expression and activity of sPLA2-IIA in HUVECs and mouse. Post treatment of cells or mouse with PEL inhibited LPS-induced expression and activity of sPLA2-IIA. Therefore, these results suggest that PEL inhibited LPS mediated expression of sPLA2-IIA.
GoldblumS.E., BrannT.W., DingX., PuginJ., TobiasP.S. (1994) Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro.Journal of Clinical Investigation, 93, 692–702.
4.
BalukP., YaoL.C., FengJ., RomanoT., JungS.S., SchreiterJ.L., YanL., ShealyD.J., McDonaldD.M. (2009) TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. Journal of Clinical Investigation, 119, 2954–2964.
5.
KudoI., MurakamiM. (2002) Phospholipase A2 enzymes. Prostaglandins and Other Lipid Mediators, 68–69, 3–58.
6.
SixD.A., DennisE.A. (2000) The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochimica et Biophysica Acta, 1488, 1–19.
7.
VadasP., PruzanskiW. (1986) Role of secretory phospholipases A2 in the pathobiology of disease. Laboratory Investigation, 55, 391–404.
8.
PruzanskiW., VadasP. (1991) Phospholipase A2–a mediator between proximal and distal effectors of inflammation. Immunology Today, 12, 143–146.
9.
WaydhasC., Nast-KolbD., DuswaldK.H., LehnertP., SchweibererL. (1989) Prognostic value of serum phospholipase A in the multitraumatized patient. Klinische Wochenschrift, 67, 203–206.
10.
PruzanskiW., VadasP., StefanskiE., UrowitzM.B. (1985) Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme. Journal of Rheumatology, 12, 211–216.
11.
VadasP., BrowningJ., EdelsonJ., PruzanskiW. (1993) Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. Journal of Lipid Mediators, 8, 1–30.
12.
TanakaK., KatoT., MatsumotoK., YoshidaT. (1993) Anti-inflammatory action of thielocin A1 beta, a group II phospholipase A2 specific inhibitor, in rat carrageenan-induced pleurisy. Inflammation, 17, 107–119.
13.
MurakamiM., NakataniY., AtsumiG., InoueK., KudoI. (1997) Regulatory functions of phospholipase A2. Critical Reviews in Immunology, 17, 225–283.
14.
NodaY., KaneyukiT., MoriA., PackerL. (2002) Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin. Journal of Agricultural and Food Chemistry, 50, 166–171.
15.
KamenickovaA., AnzenbacherovaE., PavekP., SoshilovA.A., DenisonM.S., AnzenbacherP., DvorakZ. (2013) Pelargonidin activates the AhR and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T. Toxicology Letters, 218, 253–259.
16.
HamalainenM., NieminenR., VuorelaP., HeinonenM., MoilanenE. (2007) Anti-Inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages-Volume 2007, Mediators of Inflammation, Article ID 45673, 10 pages.
17.
SchmittE., StopperH. (2001) Estrogenic activity of naturally occurring anthocyanidins. Nutrition and Cancer, 41, 145–149.
18.
HidalgoM., Martin-SantamariaS., RecioI., Sanchez-MorenoC., de Pascual-TeresaB., RimbachG., de Pascual-TeresaS. (2012) Potential anti-inflammatory, anti-adhesive, anti/estrogenic, and angiotensin-converting enzyme inhibitory activities of anthocyanins and their gut metabolites. Genes & Nutrition, 7, 295–306.
19.
OldoniT.L.C., MeloP.S., MassarioliA.P., MorenoI.A.M., BezerraR.M.N., RosalenP.L., da SilvaG.V.J., NascimentoA.M., AlencarS.M. (2016) Bioassay-guided isolation of proanthocyanidins with antioxidant activity from peanut (Arachis hypogaea) skin by combination of chromatography techniques. Food Chemistry, 192, 306–312.
20.
ZhuZ., KuangM., LamikanraO., LiuG., LiS., HeJ. (2015) Preparation and Toxicological Evaluation of Methyl Pyranoanthocyanin. Food and Chemical Toxicology, 83, 125–132.
21.
BurasJ.A., HolzmannB., SitkovskyM. (2005) Animal models of sepsis: setting the stage. Nature Reviews Drug Discovery, 4, 854–865.
22.
MenschikowskiM., HagelgansA., HempelU., LattkeP., IsmailovI., SiegertG. (2008) On interaction of activated protein C with human aortic smooth muscle cells attenuating the secretory group IIA phospholipase A2 expression. Thrombosis Research, 122, 69–76.
23.
MenschikowskiM., HagelgansA., SiegertG. (2006) Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?Prostaglandins and Other Lipid Mediators, 79, 1–33.
24.
NakanoT., OharaO., TeraokaH., AritaH. (1990) Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. Journal of Biological Chemistry, 265, 12745–12748.
25.
OkaS., AritaH. (1991) Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression. Journal of Biological Chemistry, 266, 9956–9960.
26.
CrowlR.M., StollerT.J., ConroyR.R., StonerC.R. (1991) Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. Journal of Biological Chemistry, 266, 2647–2651.
27.
BradleyJ.D., DmitrienkoA.A., KivitzA.J., GluckO.S., WeaverA.L., WiesenhutterC., MyersS.L., SidesG.D. (2005) A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. Journal of Rheumatology, 32, 417–423.
28.
ZeiherB.G., SteingrubJ., LaterreP.F., DmitrienkoA., FukiishiY., AbrahamE. (2005) LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Critical Care Medicine, 33, 1741–1748.
29.
GrassD.S., FelknerR.H., ChiangM.Y., WallaceR.E., NevalainenT.J., BennettC.F., SwansonM.E. (1996) Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. Journal of Clinical Investigation, 97, 2233–2241.
30.
BeckG., YardB.A., SchulteJ., HaakM., van AckernK., van der WoudeF.J., KaszkinM. (2003) Secreted phospholipases A2 induce the expression of chemokines in microvascular endothelium. Biochemical and Biophysical Research Communications, 300, 731–737.
31.
KimJ., BaeJ.S. (2016) ROS homeostasis and metabolism: a critical liaison for cancer therapy. Experimental and Molecular Medicine, 48, e269.
BaeJ.S., LeeW., NamJ.O., KimJ.E., KimS.W., KimI.S. (2014) Transforming Growth Factor beta-induced Protein Promotes Severe Vascular Inflammatory Responses. American Journal of Respiratory and Critical Care Medicine, 189, 779–786.
34.
MenschikowskiM., HagelgansA., HeyneB., HempelU., NeumeisterV., GoezP., JarossW., SiegertG. (2005) Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochimica et Biophysica Acta, 1733, 157–171.
35.
BaeJ.S., RezaieA.R. (2010) Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms. Thrombosis Research, 125, e9–e15.
36.
ShimoyamaY., SakamotoR., AkaboshiT., TanakaM., OhtsukiK. (2001) Characterization of secretory type IIA phospholipase A2 (sPLA2-IIA) as a glycyrrhizin (GL)-binding protein and the GL-induced inhibition of the CK-II-mediated stimulation of sPLA2-IIA activity in vitro.Biological and Pharmaceutical Bulletin, 24, 1004–1008.
